The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules
Abstract Despite a significantly improved dietary iodine supply, solitary toxic thyroid nodules (STN) are still a common clinical problem in former iodine deficient areas. Radioiodine treatment (RIT) is a well-established therapeutic option with few side effects and high success rates. As radioiodin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-08-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-18170-3 |
| _version_ | 1818497905608097792 |
|---|---|
| author | Christian Happel Wolfgang Tilman Kranert Benjamin Bockisch Amir Sabet Frank Grünwald Daniel Groener |
| author_facet | Christian Happel Wolfgang Tilman Kranert Benjamin Bockisch Amir Sabet Frank Grünwald Daniel Groener |
| author_sort | Christian Happel |
| collection | DOAJ |
| description | Abstract Despite a significantly improved dietary iodine supply, solitary toxic thyroid nodules (STN) are still a common clinical problem in former iodine deficient areas. Radioiodine treatment (RIT) is a well-established therapeutic option with few side effects and high success rates. As radioiodine biokinetics are individual for every patient, the necessary activity has to be calculated individually by a pre-therapeutic measurement of the intra-therapeutic effective half-life (EHL) in a radioiodine uptake test (RIUT). A suppressive medication with triiodothyronine (T3) or tetraiodothyronine (T4) is often needed to suppress uptake in normal thyroid tissue. Therefore, the aim of this study was to quantify the possible influence of this medication on intra-therapeutic radioiodine biokinetics. A cohort of 928 patients with STN undergoing RIUT and RIT was analysed. Patients were subdivided into 3 groups. Group T3: medication with T3 (n = 274), group T4: medication with T4 (n = 184) and group NM: no additional medication (n = 470). The T3 and T4 subgroups were further subdivided depending on the dose of thyroid hormone medication. In order to analyse the influence of thyroid hormone medication on individual intra-thyroidal biokinetics, the variance of the determined individual EHL between RIUT and RIT within the single groups and within the subgroups was investigated. EHL was significantly decreased between RIUT and RIT in the T3 and T4 subgroups (EHL: T3: 5.9 ± 1.1 d in RIUT and 3.3 ± 1.4 d in RIT (− 43%) (p < 0.05); T4: 5.9 ± 1.2 d in RIUT and 3.4 ± 1.5 d in RIT (− 42%) (p < 0.05). The decrease of EHL did not differ statistically between T3 or T4. However, both showed a highly significant difference compared to the NM group (p < < 0.05). A further subgroup analysis showed a significant dependence of the decrease in EHL related to the dose of thyroid hormone medication of 35–58% (T3) and 15–67% (T4) (p < 0.05). A significantly reduced EHL compared to RIUT in patients receiving thyroid hormone medication was detected. Moreover, a significant correlation between the dose of thyroid hormone medication (T3 or T4) and the decrease of EHL was found. Therefore, an adaption of the calculated activity should be considered in RIUT to obtain the required radiation dose in RIT of patients suffering from STN. |
| first_indexed | 2024-12-10T18:51:17Z |
| format | Article |
| id | doaj.art-d83e8fa652284545962d95ab4c927b15 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-10T18:51:17Z |
| publishDate | 2022-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-d83e8fa652284545962d95ab4c927b152022-12-22T01:37:18ZengNature PortfolioScientific Reports2045-23222022-08-011211710.1038/s41598-022-18170-3The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodulesChristian Happel0Wolfgang Tilman Kranert1Benjamin Bockisch2Amir Sabet3Frank Grünwald4Daniel Groener5Department of Nuclear Medicine, University Hospital, Goethe UniversityDepartment of Nuclear Medicine, University Hospital, Goethe UniversityDepartment of Nuclear Medicine, University Hospital, Goethe UniversityDepartment of Nuclear Medicine, University Hospital, Goethe UniversityDepartment of Nuclear Medicine, University Hospital, Goethe UniversityDepartment of Nuclear Medicine, University Hospital, Goethe UniversityAbstract Despite a significantly improved dietary iodine supply, solitary toxic thyroid nodules (STN) are still a common clinical problem in former iodine deficient areas. Radioiodine treatment (RIT) is a well-established therapeutic option with few side effects and high success rates. As radioiodine biokinetics are individual for every patient, the necessary activity has to be calculated individually by a pre-therapeutic measurement of the intra-therapeutic effective half-life (EHL) in a radioiodine uptake test (RIUT). A suppressive medication with triiodothyronine (T3) or tetraiodothyronine (T4) is often needed to suppress uptake in normal thyroid tissue. Therefore, the aim of this study was to quantify the possible influence of this medication on intra-therapeutic radioiodine biokinetics. A cohort of 928 patients with STN undergoing RIUT and RIT was analysed. Patients were subdivided into 3 groups. Group T3: medication with T3 (n = 274), group T4: medication with T4 (n = 184) and group NM: no additional medication (n = 470). The T3 and T4 subgroups were further subdivided depending on the dose of thyroid hormone medication. In order to analyse the influence of thyroid hormone medication on individual intra-thyroidal biokinetics, the variance of the determined individual EHL between RIUT and RIT within the single groups and within the subgroups was investigated. EHL was significantly decreased between RIUT and RIT in the T3 and T4 subgroups (EHL: T3: 5.9 ± 1.1 d in RIUT and 3.3 ± 1.4 d in RIT (− 43%) (p < 0.05); T4: 5.9 ± 1.2 d in RIUT and 3.4 ± 1.5 d in RIT (− 42%) (p < 0.05). The decrease of EHL did not differ statistically between T3 or T4. However, both showed a highly significant difference compared to the NM group (p < < 0.05). A further subgroup analysis showed a significant dependence of the decrease in EHL related to the dose of thyroid hormone medication of 35–58% (T3) and 15–67% (T4) (p < 0.05). A significantly reduced EHL compared to RIUT in patients receiving thyroid hormone medication was detected. Moreover, a significant correlation between the dose of thyroid hormone medication (T3 or T4) and the decrease of EHL was found. Therefore, an adaption of the calculated activity should be considered in RIUT to obtain the required radiation dose in RIT of patients suffering from STN.https://doi.org/10.1038/s41598-022-18170-3 |
| spellingShingle | Christian Happel Wolfgang Tilman Kranert Benjamin Bockisch Amir Sabet Frank Grünwald Daniel Groener The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules Scientific Reports |
| title | The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules |
| title_full | The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules |
| title_fullStr | The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules |
| title_full_unstemmed | The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules |
| title_short | The influence of thyroid hormone medication on intra-therapeutic half-life of 131I during radioiodine therapy of solitary toxic thyroid nodules |
| title_sort | influence of thyroid hormone medication on intra therapeutic half life of 131i during radioiodine therapy of solitary toxic thyroid nodules |
| url | https://doi.org/10.1038/s41598-022-18170-3 |
| work_keys_str_mv | AT christianhappel theinfluenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT wolfgangtilmankranert theinfluenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT benjaminbockisch theinfluenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT amirsabet theinfluenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT frankgrunwald theinfluenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT danielgroener theinfluenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT christianhappel influenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT wolfgangtilmankranert influenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT benjaminbockisch influenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT amirsabet influenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT frankgrunwald influenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules AT danielgroener influenceofthyroidhormonemedicationonintratherapeutichalflifeof131iduringradioiodinetherapyofsolitarytoxicthyroidnodules |